Newsletter Subscription

Enter Name and Email

23 August 2011 - Just published: analgesic actions of the anti-fibromyalgia drug milnacipran

Fibromyalgia syndrome (FMS) is a chronic painful condition that is poorly diagnosed and for which few treatments are currently available. Among these, the dual noradrenaline and serotonin reuptake inhibitors, milnacipran and duloxetine, are among the most commonly utilised, as well as the tricyclic reuptake inhibitor, amitriptyline. Milnacipran (Ixel ®, Savella ®) was approved by the FDA as a treatment for FMS in 2009 on the basis of successful clinical trials. The present studies describe its activity in experimental models of cold or mechanical allodynia and of polyarthritis in rodents. The results show that milnacipran has favorable activity in these experimental modesl of pain and suggest that drugs exhibiting dual noradrenaline and serotonin reuptake inhibition could have utility in the treatment of diverse pain conditions.

For more information concerning Adrian Newman-Tancredi's expertise in this field, Contact.


Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain.

Berrocoso E, Mico JA, Vitton O, Ladure P, Newman-Tancredi A, Depoortère R, Bardin L.
Eur J Pharmacol. 2011 Mar 25; 655(1-3):46-51.



Effects of milnacipran, duloxetine and indomethacin, in polyarthritic rats using the Randall-Selitto model.

Mico JA, Berrocoso E, Vitton O, Ladure P, Newman-Tancredi A, Bardin L, Depoortère R.
Behav Pharmacol. 2011 Sep; 22(5&6):599-606.